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SUMMARY
The molecular diagnosis of Y-chromosomal microdeletions is a common routine genetic test which is part of the diagnostic
workup of azoospermic and severe oligozoospermic men. Since 1999, the European Academy of Andrology (EAA) and the European
Molecular Genetics Quality Network (EMQN) have been actively involved in supporting the improvement of the quality of the diag-
nostic assays by publication of the laboratory guidelines for molecular diagnosis of Y-chromosomal microdeletions and by offering
external quality assessment trials. The present revision of the 2004 laboratory guidelines summarizes all the clinical novelties related
to the Y chromosome (classic, partial and gene-specific deletions, genotype–phenotype correlations, methodological issues) and pro-
vides an update on the results of the quality control programme. These aspects also reflect the consensus of a large group of special-
ists present at a round table session during the recent Florence-Utah-Symposium on ‘Genetics of male infertility’ (Florence, 19–21
September, 2013). During the last 10 years the gr/gr deletion has been demonstrated as a significant risk factor for impaired sperm
production. However, the screening for this deletion type in the routine diagnostic setting is still a debated issue among experts. The
original basic protocol based on two multiplex polymerase chain reactions remains fully valid and appropriate for accurate diagnosis
of complete AZF deletions and it requires only a minor modification in populations with a specific Y chromosome background.
However, in light of novel data on genotype–phenotype correlations, the extension analysis for the AZFa and AZFb deletions is now
routinely recommended. Novel methods and kits with excessively high number of markers do not improve the sensitivity of the test,
may even complicate the interpretation of the results and are not recommended. Annual participation in an external quality control
programme is strongly encouraged. The 12-year experience with the EMQN/EAA scheme has shown a steep decline in diagnostic
(genotyping) error rate and a simultaneous improvement on reporting practice.
INTRODUCTION
After the Klinefelter syndrome, Y-chromosomal microdele-
tions are the second most frequent genetic cause of male infertil-
ity. In the last decade, many investigators have described the
occurrence of microdeletions in infertile patients around the
world and the molecular diagnosis of deletions has become an
important test in the diagnostic workup of male infertility (Vogt
et al., 1996; Krausz & Degl’Innocenti, 2006; Simoni et al., 2008).
Microdeletions occur in about one in 4000 men in the general
population but its frequency is significantly increased among
infertile men. Azoospermic men have a higher incidence of
microdeletions than oligozoospermic men and consequently
deletion frequency found in different laboratories may vary from
2 to 10% (or even higher, Fig. 1) reflecting the composition of
the study population (Krausz et al., 2001; Simoni et al., 2008; Lo
Giacco et al., 2013). Typically, routine laboratories receiving
referrals from outside institutions, without controlled patient
selection, have a much lower incidence, <2%.
The published data and the quality control programme experi-
ence showed that diagnostic protocols can be quite different and
© 2013 American Society of Andrology and European Academy of Andrology Andrology, 2014, 2, 5–19 5
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
ISSN: 2047-2919 ANDROLOGY
that inaccurate or wrong diagnoses occur as well, suggesting the
necessity of both standardization and quality control (Simoni,
2001). Therefore, the European Academy of Andrology (EAA)
and the European Molecular Genetics Quality Network (EMQN)
jointly supported the publication of two ‘Laboratory guidelines
for molecular diagnosis of Y-chromosomal microdeletions’
(Simoni et al., 1999, 2004) and started offering external quality
assessment (EQA).
During the last 9 years, novel data concerning gene-specific
deletions, partial AZFc deletions/duplications and genotype–
phenotype correlations have been accumulated. All these issues
together with some methodological aspects which urged to be
clarified, and an update on the EAA/EMQN AZF quality control
scheme’s activity is summarized in this study.
STRUCTURE OF THE MALE-SPECIFIC REGION OF THE Y
CHROMOSOME (MSY)
The complete physical map and sequence of MSY have been
available since 2003 (Skaletsky et al., 2003). This information
was obtained by sequencing and mapping 220 BAC clones
containing portions of the MSY from one man. The use of only
one individual was necessary because, owing to the presence of
repetitive sequences with only minute differences characterizing
the individual copies of each sequence (sequence family vari-
ants, SFV), interindividual allelic variation or polymorphisms
would have prevented the accurate mapping of SFV necessary to
allocate the BAC clones. Three classes of sequences were found
in MSY: X-transposed (with 99% identity to the X chromosome),
X-degenerate (single-copy genes or pseudogene homologues of
X-linked genes) and ampliconic. Ampliconic sequences are char-
acterized by sequence pairs showing nearly complete (>99.9%)
identity, organized in massive palindromes. According to current
knowledge, the reference MSY contains 156 transcription units
including 78 protein-coding genes encoding 27 proteins. Ampli-
conic sequences comprise 60 coding genes and 74 non-coding
transcription units mostly grouped in families and expressed
mainly or only in the testis. Ampliconic sequences recombine
through gene conversion, that is, non-reciprocal transfer of
sequence information occurring between duplicated sequences
within the chromosome, a process which maintains the >99.9%
identity between repeated sequences organized in pairs in
inverted orientation within palindromes.
Besides maintaining the gene content, this peculiar sequence
organization provides the structural basis for deletions and rear-
rangements. It is widely accepted that complete AZF deletions
arise invariably through Non-Allelic Homologous Recombina-
tion (NAHR) which takes place between highly homologous
repeated sequences with the same orientation leading to loss of
the genetic material between them. Considering the architecture
of the MSY, several different deletions are hypothetically possi-
ble (Kuroda-Kawaguchi et al., 2001; Yen, 2001; Repping et al.,
2003) and those which are clinically relevant for male infertility,
based on current knowledge, are briefly described below.
MECHANISM AND TYPE OF DELETIONS
Three discrete AZFa, AZFb and AZFc regions were originally
characterized by careful mapping of the MSY of a large number
of men with microdeletions when the sequence of the Y chromo-
some was not completely known (Vogt et al., 1996). Subse-
quently, thanks to the fine molecular characterization of the
deletions, a new model of deletions, in which the AZFb and AZFc
regions are overlapping, have been proposed (Fig. 2). In addi-
tion, the AZFb and AZFbc deletions have been suggested to be
the consequence of at least three different deletions patterns
(Repping et al., 2002) (Fig. 2). While the new nomenclature is
more appropriate in biological terms, from the practical, clinical
point of view either nomenclature can be adopted for the com-
plete AZFb (P5/proximal P1) and AZFc (b2/b4) deletions. On the
other hand, the distinction between the two AZFbc subtypes
(P5/distal P1 and P4/distal P1) does have clinical relevance (see
below). We additionally provide information on the genomic
localization of the sY-loci used for the AZF analyses
Figure 1 Worldwide frequencies of AZF deletions in infertile men (reprinted from Simoni et al., 2008 with publisher’s permission). Percentages are coded
in colours according to the legend. Note: Sweden, Germany and Austria show the lowest incidence. However, the composition of the study populations dif-
fered in terms of the proportion of azoospermic vs. oligozoospermic patients which may also contribute to the observed differences.
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(Appendix C), which should be used to describe deletions fol-
lowing the HGVS nomenclature as part of a standard practice.
The description of the AZFc (b2/b4) deletion is given in ‘report
examples’.
The AZFa region is about 1100 kb long and contains the sin-
gle-copy genes USP9Y (former DFFRY) and DDX3Y (former
DBY). Recent data obtained simultaneously by different groups
identify the origin of complete AZFa deletions in the homolo-
gous recombination between identical sequence blocks within
the retroviral sequences in the same orientation HERVyq1 and
HERVyq2 (Blanco et al., 2000; Kamp et al., 2000; Sun et al.,
2000). Within these retroviruses, recombination can occur in
either one of two identical sequence blocks (ID1 and ID2), giving
rise to two major pattern of deletions slightly different in their
precise breakpoints (Kamp et al., 2000; Sun et al., 2000; Kamp
et al., 2001). In any case, the complete deletion of the AZFa
region removes about 792 kb including both USP9Y and DDX3Y
genes, the only two genes in the AZFa region.
The type and mechanism of deletions of the AZFb and AZFc
region have been clarified by Kuroda-Kawaguchi et al. (2001).
Both regions together comprise 24 genes, most of which are
present in multiple copies for a total of 46 copies. The complete
deletion of AZFb removes 6.2 Mb (including 32 copies of genes
and transcription units) and results from homologous recombi-
nation between the palindromes P5/proximal P1 (Repping et al.,
2002). The AZFc region includes 12 genes and transcription
units, each present in a variable number of copies making a total
of 32 copies (Repping et al., 2003). The classical complete dele-
tion of AZFc, the most frequent pattern among men with dele-
tions of the Y chromosome, removes 3.5 Mb, originates from the
homologous recombination between amplicons b2 and b4 in
palindromes P3 and P1, respectively, and removes 21 copies of
genes and transcription units (Kuroda-Kawaguchi et al., 2001).
Deletions of both AZFb and AZFc together occur by two major
mechanisms involving homologous recombination between P5/
distal P1 (7.7 Mb and 42 copies removed) or between P4/distal
P1 (7.0 Mb, 38 copies removed) (Repping et al., 2002).
Therefore, according to the present knowledge, the following
recurrent microdeletions of the Y chromosome are clinically rel-
evant and are found in men with severe oligo- or azoospermia
(Fig. 2):
• AZFa,
• AZFb (P5/proximal P1),
• AZFbc (P5/distal P1 or P4/distal P1),
• AZFc (b2/b4).
The most frequent deletion type is the AZFc region deletion
(~80%) followed by AZFa (0.5–4%), AZFb (1–5%) and AZFbc
(1–3%) deletion. Deletions which are detected as AZFabc are
most likely related to abnormal karyotype such as 46,XX male or
iso(Y) (Lange et al., 2009).
Gr/gr deletion
The AZFc region is particularly susceptible to NAHR events
which may cause the formation of both partial deletions and
duplications leading to gene dosage variations (Kuroda-Kawagu-
chi et al., 2001; Yen, 2001; Krausz et al., 2011). Although a num-
ber of different partial AZFc deletions have been described, only
one of them is of potential clinical interest. This is the ‘gr/gr’
deletion, named after the fluorescent probes (‘green’ and ‘red’)
used when first described (Repping et al., 2003). Although it
removes half of the AZFc gene content (genes with exclusive or
predominant expression in the germ cells), its clinical signifi-
cance is still a matter of debate, because carriers may exhibit
highly variable spermatogenic phenotypes ranging from azoo- to
normozoospermia. Clearly the effect of the deletion is largely
dependent on the ethnic and geographic origin of the study pop-
ulation. In fact, the frequency and phenotypic effect may vary
among different ethnic groups, on the basis of the Y chromo-
some background; for example, in specific Y haplogroups, such
as D2b, Q3 and Q1, common in Japan and certain areas of China,
the deletion is fixed and apparently does not have negative
effects on spermatogenesis (Sin et al., 2010; Yang et al., 2010).
Controversies are also related to selection biases (lack of ethnic/
geographic matching of cases and controls; inappropriate
Figure 2 Schematic representation of the Y chromosome and the current microdeletion model (Repping et al., 2002). Repetitive sequences (colour coded
palindromes) explain the origin of deletions in the AZFbc region by homologous recombination between identical sequences. The location of the STS prim-
ers suggested by the present guidelines is indicated by dashed lines. As four copies of the DAZ gene are normally present on the Y chromosome, the STS
primers sY254, sY255 amplify four loci in AZFc. The AZFc (b2/b4) deletion is by far the most frequent type (~80%) of Y-chromosomal microdeletions found
in men with severe oligo/azoospermia.
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selection of infertile and control men) and methodological issues
(lack of confirmation of gene loss). Many efforts have been done
to clarify the molecular basis for the highly variable phenotypic
presentation of this deletion type. It has been previously
described that the loss of DAZ1/DAZ2 and CDY1 is prevalent (or
even specific) in carriers with impaired sperm production (Fer-
nandes et al., 2002; Ferlin et al., 2005; Giachini et al., 2005) while
it was hypothesized that the restoration of normal AZFc gene
dosage in case of gr/gr deletion followed by b2/b4 duplication
may explain the lack of effect on sperm count (Repping et al.,
2003). In this regard, a large multicentre study, based on a com-
bined method (gene dosage, definition of the lost DAZ and CDY1
genes, Y hgr definition), was performed on Caucasians (Krausz
et al., 2009). Notwithstanding the detailed characterization of
subtypes of gr/gr deletions based on the type of missing gene
copies and the detection of secondary rearrangements (deletion
followed by b2/b4 duplication) together with the definition of Y
haplogroups, it was impossible to define a specific pattern which
would be associated with either a ‘neutral’ or a ‘pathogenic’
effect. On the contrary, studies dealing with Asian populations
seem to support the hypothesis about a deletion subtype-depen-
dent phenotypic effect and about the importance of the Y back-
ground on which the deletion arises (Yang et al., 2010; Choi
et al., 2012). In addition to classic case/control studies aiming to
define whether the gr/gr deletion confers a risk for spermato-
genic disturbances, the analysis of consecutive patients through
cross-sectional cohort analysis indicates that the gr/gr deletion
has an effect even within the normal range of sperm count. It
was observed, indeed, that normozoospermic carriers have a sig-
nificantly lower sperm count, compared to men with intact Y
chromosome (Visser et al., 2009). In addition, Yang et al. (2006)
reported that, in the Chinese population, the deletion frequency
drastically decreases in subgroups with sperm concentrations
>50 9 106/mL.
The screening for gr/gr deletion is based on a PCR plus/minus
method of two markers (sY1291 and sY1191) (Repping et al.,
2003) and the diagnosis is based on the absence of marker
sY1291 and presence of sY1191. It is worth noticing that a 5%
false deletion rate has been detected in the multicenter study
(Krausz et al., 2009), underlining the importance of the optimi-
zation of the PCR conditions and of additional confirmatory
steps such as simplex PCR and eventually gene dosage analysis
(Giachini et al., 2005; Choi et al., 2012). The definition of the Y
haplogroup is indicated in Asian patients to exclude constitutive
deletions which are unlikely to affect spermatogenesis (see
above).
Clinical implications
As stated above, the heterogeneity of the study populations
available in the literature complicates a reliable meta-analysis.
However, four meta-analyses have been attempted on this topic
all achieving significant odds ratios reporting on average 2- to
2.5-fold increased risks of reduced sperm output/infertility
(T€uttelmann et al., 2007; Visser et al., 2009; Navarro-Costa et al.,
2010; Stouffs et al., 2011). Therefore, the gr/gr deletion repre-
sents a unique example in andrology of a confirmed significant
genetic risk factor for impaired sperm production. For instance,
in the Italian population, gr/gr deletions confers a 7.9-fold
increased risk for spermatogenic impairment (OR = 7.9, 95% CI
1.8–33.8) (Ferlin et al., 2005; Giachini et al., 2008).
A gr/gr deletion (i.e. a genetic risk factor for impaired sperm
production) will be obligatorily transmitted to the male off-
spring. The partial deletion may expand to a complete AZFc
deletion (i.e. a clear-cut causative factor for spermatogenic
impairment) in the next generations (Zhang et al., 2007), but
data are currently sparse to draw final conclusions on this spe-
cific risk. Gr/gr deletions have also been proposed as genetic risk
factor for testis cancer (Nathanson et al., 2005; Linger et al.,
2007) but this association still awaits further confirmation on
large independent study populations.
The low cost of the test may justify its routine testing in those
populations for which robust and consistent data with risk esti-
mate are available (at present Italian, Spanish, Dutch and Chi-
nese). Currently, however, no general agreement to advise
routine testing has been reached (T€uttelmann et al., 2007;
Krausz et al., 2011; Stouffs et al., 2011).
Isolated AZF gene-specific deletions
Although some authors found an extraordinary high frequency
of single AZF gene deletions (Ferlin et al., 1999; Foresta et al.,
2000), these data are in stark contrast with the general experi-
ence accumulated in >2000 patients tested elsewhere (Silber
et al., 1998; Sun et al., 1999; Krausz et al., 1999a,b; Krausz et al.,
2001; Simoni et al., 2008). Gene-specific deletions are extremely
rare, and all the five confirmed deletions (with the definition of
the breakpoints) removed totally or partially the USP9Y gene
belonging to the AZFa region (Tyler-Smith & Krausz, 2009). None
of the deletions was because of NAHR and thus are likely to be
unique, supporting the extreme rarity of the occurrence of these
events. The associated semen/testis phenotype is largely variable
among USP9Y deletion carriers (from azoospermia caused by
hypospermatogenesis to normozoospermia) indicating that this
gene rather acts as a fine tuner than an essential factor for sper-
matogenesis. Based on the absence of other than USP9Y gene
deletions in the literature, screening for isolated gene-specific
deletions is not advised in the routine diagnostic setting. Given
that some of the commercially available kits contain gene-spe-
cific markers, much care has to be taken both of the validation
of suspected single-gene deletions as well as of the interpreta-
tion of the results.
Genotype/phenotype correlation of complete AZF deletions
AZF deletions are specific for spermatogenic failure as no
deletions have been reported in a large number of normozoo-
spermic men (Krausz et al., 2003; Simoni et al., 2008). Although
‘fertility’ can be compatible with these deletions, it simply
reflects the fact that natural fertilization may occur even with
low sperm counts depending on the female partner’s fertility
status. For this reason, it is more appropriate to consider Y
deletions as a cause of oligo/azoospermia rather than a cause
of ‘infertility’.
Deletions of the entire AZFa region invariably result in ser-
toli cell only syndrome (SCOS) and azoospermia (Vogt et al.,
1996; Krausz et al., 2000; Kamp et al., 2001; Hopps et al., 2003;
Kleiman et al., 2012). The diagnosis of a complete deletion of
the AZFa region implies the virtual impossibility to retrieve
testicular spermatozoa for intracytoplasmic sperm injection
(ICSI).
Complete deletions of AZFb and AZFbc (P5/proximal P1, P5/
distal P1, P4/distal P1) are characterized by a histological picture
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of SCOS or spermatogenetic arrest resulting in azoospermia.
Several reports have shown that similar to the complete dele-
tions of the AZFa region, no spermatozoa are found upon
attempts of testicular sperm extraction (TESE) in these patients
(Krausz et al., 2000; Hopps et al., 2003; Kleiman et al., 2011).
However, in three cases, spermatid arrest and even crypto/oligo-
zoospermia has been reported in association with complete
AZFb or AZbc deletions (Longepied et al., 2010; Soares et al.,
2012). The biological explanation of the unusual phenotypes
remains unclear, both Y background effect and differences in the
exact extent of the deletions may account for it. In fact, a smaller
deletion, that is, a proximal breakpoint at P4 may be associated
with the retention of AZFb gene copies such as XKRY, CDY2 and
HSFY. It has been therefore proposed that the associated pheno-
type is more severe in case of complete removal of the AZFb
region. With very few exceptions reported in the literature, the
diagnosis of complete deletions of AZFb or AZFbc (P5/proximal
P1, P5/distal P1, P4/distal P1) implies that the chance for testicu-
lar sperm retrieval is virtually zero even with micro-TESE (Bran-
dell et al., 1998).
Deletions of the AZFc region (b2/b4) are associated with a
variable clinical and histological phenotype (Reijo et al., 1996;
Luetjens et al., 2002; Oates et al., 2002). In general, AZFc dele-
tions are compatible with residual spermatogenesis and thus
can be found also in men with severe oligozoospermia and, in
rare cases, may even be transmitted naturally to the male off-
spring (K€uhnert et al., 2004 and references therein). In men with
azoospermia and AZFc deletion there is approximately 50%
chance of retrieving spermatozoa from TESE and children can
be conceived by ICSI (Kent-First et al., 1996; Mulhall et al., 1997;
Kamischke et al., 1999; Jiang et al., 1999; Kleiman et al., 1999;
Page et al., 1999; Cram et al., 2000; van Golde et al., 2001; Oates
et al., 2002; Peterlin et al., 2002; Ferlin et al., 2007; Simoni et al.,
2008; Lo Giacco et al., 2013). The TESE success rate largely
depends on the technique used and can be as low as 9% (Lo Gi-
acco et al., 2013) and as high as 70–80% following micro-TESE
(Hopps et al., 2003). According to one report, the presence of 45,
X cell lines in blood may be a negative predictive factor for
spermatogenesis (Jaruzelska et al., 2001).
INDICATIONS FOR MOLECULAR SCREENING OF THE Y
CHROMOSOME
Diagnosis of a microdeletion of the Y chromosome permits
the cause of the patient’s azoospermia/oligozoospermia to be
established and to formulate a prognosis. In which patients
should molecular screening of the Y chromosome be per-
formed? The world literature, now based on several thousands
of patients screened, indicates that, as a rule, clinically relevant
deletions are found in patients with azoospermia or severe oli-
gozoospermia with sperm concentrations <2 9 106/mL. Very
rarely, deletions can be found in infertile patients with sperm
concentration between 2 and 5 9 106/mL (Maurer & Simoni,
2000; Lo Giacco et al., 2013). We provide a flow chart with these
indications and including the recommended analytic steps in
Fig. 3. The usual clinical parameters such as hormone levels,
testicular volume, varicocoele, maldescended testis, infections,
etc. do not have any predictive value (Maurer et al., 2001; Oates
et al., 2002; Tomasi et al., 2003; Simoni et al., 2008). In general,
molecular analysis of the Y chromosome is not indicated in
patients with chromosomal abnormalities (except 46,XY/45,X
karyotype), obstructive azoospermia (unless FSH is above the
normal limit) or hypogonadotropic hypogonadism. However, in
the literature there are a number of examples of deletion carri-
ers among non-idiopathic infertile men, for example, with a
testicular tumour or after chemo-/radiotherapy, which would
be considered to explain the spermatogenic failure. Therefore,
the presence of any diagnosis accompanied by azoo- or severe
oligozoospermia should be an indication for AZF testing. For
instance, in men belonging to the above semen categories, AZF
screening is important before varicocoelectomy because dele-
tion carriers will most likely not benefit from the surgical
procedure.
After a high incidence of AZF deletions in Klinefelter patients
had been reported in two small studies (Mitra et al., 2006; Had-
jkacem-Loukil et al., 2009), the question arose whether deletion
screening should be routinely be performed in these men.
However, the described deletions were mainly diagnosed by only
isolated markers of the AZFa and/or the AZFb region, not con-
firmed by additional analyses, and should probably be regarded
as methodological artefacts. In contrast, three much larger stud-
ies did not find any AZF deletions in Klinefelter patients (Choe
et al., 2007; Simoni et al., 2008; Rajpert-De Meyts et al., 2011).
Patients with azoospermia who may be candidate for TESE/
ICSI should be offered deletion screening because TESE should
not be recommended in cases of complete deletion of the AZFa
region. Micro-TESE in azoospermic carriers of deletions of the
AZFb or AZFbc regions with proximal breakpoint in the P4 palin-
drome may be eventually attempted. However, the patient
should be fully informed about the very low/virtually zero
chance to retrieve spermatozoa. A standard biopsy (without
microsurgical equipment) should never be attempted in these
cases. Therefore, the diagnosis of a deletion has prognostic value
and can influence therapeutic options.
GENETIC COUNSELLING
Genetic counselling is mandatory to provide information
about the risk of conceiving a son with impaired spermatogene-
sis. In case of partial AZFa or AZFb and AZFc deletion, the coun-
selling (with AZF testing) is relevant also for other male
members of the family as transmission of these type of deletions
has been reported in the literature (Krausz et al., 2006; Luddi
et al., 2009; Plotton et al., 2010). Complete AZFa, AZFb, AZFbc
or AZFabc deletion are generally incompatible with sperm
production thus family screening is not indicated.
Several studies have been published about ICSI performed
in couples with male partners carrying AZFc deletions (Kent-
First et al., 1996; Mulhall et al., 1997; Jiang et al., 1999; Kami-
schke et al., 1999; Kleiman et al., 1999; Page et al., 1999; Cram
et al., 2000; van Golde et al., 2001; Oates et al., 2002; Peterlin
et al., 2002; Stouffs et al., 2005; Mau Kai et al., 2008; Simoni
et al., 2008; Mateu et al., 2010; Lo Giacco et al., 2013). Although
a lower fertilization rate and embryo quality (van Golde et al.,
2001), a significantly impaired blastocyst rate (Mateu et al.,
2010) and lower overall success of ICSI (Simoni et al., 2008)
have been reported, the majority of studies report no signifi-
cant differences in fertilization and pregnancy rates between
men with or without Y deletion. While the deletion of the
father will be obligatory transmitted to the son, who will have
impaired sperm production, the exact testicular phenotype
cannot be predicted because of the different genetic
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GUIDELINES FOR Y- MICRODELETION TESTING 2013 ANDROLOGY
background and the impact of environmental factors on repro-
ductive functions and on the fertility potential of father and
son.
Concerns have been raised about the potential risk for Turn-
er’s syndrome (45,X) in the offspring and other phenotypic
anomalies associated with sex chromosome mosaicism,
(A)
(B)
Figure 3 Flow chart with indication for AZF screening, common analytical steps and consequences: (A) basic analyses, (B) extension analyses.
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including ambiguous genitalia. Data on men with Y microdele-
tions (Siffroi et al., 2000; Rajpert-De Meyts et al. 2011) and in
patients bearing a mosaic 46,XY/45,X karyotype with sexual
ambiguity and/or Turner stigmata (Patsalis et al., 2002) suggest
that some Yq microdeletions are associated with an overall
Y-chromosomal instability which might result in the formation
of 45,X cell lines. The number of reported ICSI babies born
from fathers affected by Yq microdeletions is still relatively low
being close to 50 (Kent-First et al., 1996; Mulhall et al., 1997;
Jiang et al., 1999; Kamischke et al., 1999; Kleiman et al., 1999;
Cram et al., 2000; van Golde et al., 2001; Oates et al., 2002;
Peterlin et al., 2002; Choi et al., 2004; Kihaile et al., 2004;
Stouffs et al., 2005; Mau Kai et al., 2008; Simoni et al., 2008;
Mateu et al., 2010; Lo Giacco et al., 2013). It appears that the
children are phenotypically normal, except for one son born
with pulmonary atresia and a hypoplastic right ventricle (Page
et al., 1999) and no ambiguous genitalia or Turner syndrome
have been observed among them. Considering that embryos
bearing a 45,X karyotype have a very high risk of spontaneous
abortion, it would be important to know whether there is a
higher incidence of spontaneous abortion among the partners
of Y deleted men. Two studies provide data on the aneuploidy
rate in embryos by performing preimplantation genetic diag-
nosis in embryos derived from Y chromosome deletion carri-
ers. In the first study, no sex chromosome anomalies have
been found (Stouffs et al., 2005), whereas in the other a high
percentage of abnormal embryos was observed, with a signifi-
cant increase in the percentage of embryos with monosomy X
in respect to oligozoospermic patients without Y deletion
(Mateu et al., 2010). This implies that caution has to be taken
when this risk is discussed with the patients and before pre-
implantation or pre-natal diagnosis is proposed.
Recently, Jorgez et al. (2011) reported the detection of
haploinsufficiency of the SHOX (Short-stature HOmeoboX-con-
taining) gene located in the pseudoautosomal region 1 (PAR1)
on the short arm of the Y chromosome in 5.4% of men with AZF
deletions and a normal karyotype. They raised the question
about the importance of screening for SHOX-linked copy num-
ber variations in men carrying Yq microdeletions. However, a
subsequent much larger multicentre study did not find an asso-
ciation between Y-chromosomal microdeletions and SHOX hap-
loinsufficiency, implying that deletion carriers have no
augmented risk of SHOX-related pathologies (short stature and
skeletal anomalies) (Chianese et al., 2013).
In conclusion, the indication for molecular diagnosis of Y-
chromosomal microdeletions is based on sperm concentration
and it is strongly advised in patients affected by azoospermia
and severe oligozoospermia (<5 9 106/mL). AZF testing has
prognostic value for sperm retrieval and in case spermatozoa
can be found in the ejaculate or by testicular biopsy (micro-
TESE instead of conventional TESE is strongly advised) the dele-
tion will be obligatory transmitted to the male offspring. The fer-
tilization rate and pregnancy rate seem to be similar to that
obtained in men without Y microdeletion, but a lower embryo
quality and blastocyst rate have also been described. We still do
not have conclusive information about the real risk for Turner
syndrome, ambiguous genitalia or other chromosomal anoma-
lies because data are scarce and discordant. Analysis of the male
members of the family is advised in case of AZFc or partial AZFb
or AZFa deletions. Moreover, karyotype is indicated in the
presence of AZFc or Yq terminal deletions to rule out 46,XY/45,X
mosaicism.
GUIDELINES FOR DIAGNOSTIC TESTING
Diagnostic testing for deletions is performed by PCR amplifi-
cation of selected regions of the Y chromosome. MSY-specific
STS primers amplify both anonymous sequences of the chro-
mosome or genes and can be now mapped precisely (Skaletsky
et al., 2003). Although the map of the MSY is now known, still
virtually nothing is known about the role of the individual
genes and transcription units in spermatogenesis and their
causal role for infertility. It has been shown that using STS
primers specific for discrete genes does not increase the detec-
tion rate of clinically relevant microdeletions in DNA samples
from ICSI candidates (Silber et al., 1998; Krausz et al., 1999a,
2001; Peterlin et al., 2002). Therefore, it remains basically
unimportant whether the STS primers used amplify anony-
mous regions or specific MSY genes. What is important for the
diagnosis is that the panel of STS primers is derived from
regions of the Y chromosome which are not polymorphic and
are well-known to be deleted specifically in men affected by ol-
igo-/azoospermia according to the known, clinically relevant
microdeletion pattern. The sequence of the MSY and the mech-
anism underlying the microdeletions have shown definitely
that a putative fourth AZFd region postulated by Kent-First
et al. (1999) (and considered in a popular commercial kit) does
not exist.
PCR format and internal quality control
The PCR amplification of genomic DNA for clinical diagnosis
requires strict compliance with good laboratory practice and
basic principles of quality control. Guidelines for internal quality
control should be carefully followed when implementing the
diagnostics of Y-chromosomal microdeletions.
In parallel to the patient’s DNA sample, a female sample has
to be processed as a control for DNA contamination during the
whole procedure. Each set of PCR reactions should be carried
out at least in duplex or, even better, multiplex PCR. The multi-
plex format is helpful to distinguish a negative result from a
technical failure through the use of an internal control. An
appropriate internal PCR control in AZF diagnostics is the ZFX/
ZFY gene because the primers amplify a unique fragment both
in male and female DNA respectively. Positive and negative con-
trols must be run in parallel with each multiplex, that is, with
each set of primers. Appropriate positive and negative controls
are a DNA sample from a man with normal spermatogenesis and
from a woman respectively. In addition, a water sample, which
contains all reaction components but water instead of
DNA, must be run with each set of primers as control for
contamination.
In summary, the diagnostics of Y-chromosomal microdele-
tions should be performed by multiplex (at least duplex) PCR
amplification of genomic DNA, using the ZFX/ZFY as internal
PCR control. A DNA sample from a fertile male and from a
women and a blank (water) control should be run in parallel
with each multiplex.
Basic set of STS primers
In principle, the analysis of only one non-polymorphic STS
locus in each AZF region is sufficient to determine whether any
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STS deletion is present in AZFa, AZFb or AZFc. However, analy-
sing two STS loci in each region reinforces diagnostic accuracy,
as deletions involve well-defined regions including many STS
loci. Therefore, the concept that at least two STS loci in each
AZF region should be analysed remains valid. Based on the
experience of many laboratories, the results of external quality
control and considering the multiplex PCR format, the first
choice of STS primers recommended in the previous versions
of the guidelines remains valid (Fig. 3A). These primers
include:
For AZFa: sY84, sY86
For AZFb: sY127, sY134
For AZFc: sY254, sY255 (both in the DAZ gene)
These STS primers have been shown to give robust and repro-
ducible results in multiplex PCR reactions by several laboratories
and in external quality control trials. However, it must be noted
that according to the latest high-quality sequencing, there is a
mismatch in the middle of the sequences of the primer sY84-F
(which does not preclude the efficacy of amplification) and thus
the sequence has been changed in the table accordingly. Con-
cerning the sY84-R a SNP (rs72609647) is present in the 5th
nucleotide of the primer sequence. In case of amplification fail-
ure, an alternative STS nearby sY84 should be tested; for neigh-
bouring markers see the ‘MSY breakpoint mapper’, http://
breakpointmapper.wi.mit.edu/ (Lange et al., 2008). The SRY
gene should be included in the analysis as a control for the tes-
tis-determining factor on the short arm of the Y chromosome
and for the presence of Y-specific sequences when the ZFY gene
is absent (e.g. in XX males). Testing for ZFX is relevant not only
for the female control DNA but also in SRY negative 46,XX males
as it will be the only positive marker.
In summary, the set of PCR primers which should be used in
multiplex PCR reactions as best choice for the diagnosis of mic-
rodeletion of the AZFa, AZFb and AZFc region includes: sY14
(SRY), ZFX/ZFY, sY84, sY86, sY127, sY134, sY254, sY255. The loca-
tion of these primers on the Y chromosome is indicated in Fig. 2.
The sequence of the primers and an example of a PCR protocol
are reported in the Appendix. The use of this primer set will
enable the detection of almost all clinically relevant deletions
and of over 95% of the deletions reported in the literature in the
three AZF regions and is sufficient for routine diagnostics. Adop-
tion of this favourite set of primers by all laboratories is strongly
recommended as it allows a minimal standardization and good
comparison of laboratory performance and interlaboratory
variability.
Significance of the basic primer set and extension analysis
AZFa
The molecular analysis of the AZFa region involves the use of
the two STS markers sY84 and sY86. Both markers are located
upstream of the USPY9 and DDX3Y genes and are anonymous.
According to the pathogenic mechanism of the deletion and cur-
rent experience, once a deletion of both sY84 and sY86 is
detected, the probability of dealing with a complete deletion is
very high. However, as partial AZFa deletions have been
described in the literature and their phenotypic expression is
milder than the complete ones (Krausz et al., 2006), the defini-
tion of the extension of the deletion is now compulsory (in
contrast to previous guidelines).
The determination of the extension of the deletion (complete/
not complete) should be performed by using the STS primers
sY82 (present), sY83 (absent or present depending on the type of
breakpoint) or sY1064 (absent) for the proximal border and
sY1065 or sY1182 (absent), sY88 (present) for the distal border
(Fig. 3B). The marker sY87 is not recommended anymore
because it is located between the two AZFa genes. A more
sophisticated determination of the breakpoints can be obtained
with the protocol suggested by Kamp et al. (2001). If only one of
the two AZFa STS loci (only sY84 or only sY86) is deleted and
amplification failures can be excluded, the AZFa region should
be studied in more detail testing for the presence/absence of the
two AZFa genes (DDX3Y and USP9Y) and the borders according
to the map provided by Kamp et al. (2001) or the definition of
the breakpoints can be performed by consulting the previously
mentioned publicly available database ‘MSY breakpoint
mapper’. This event, however, is presently considered to be
extraordinarily rare.
AZFb (P5/proximal P1)
The two anonymous markers sY127 and sY134 are located in
the median and distal part of the AZFb region. According to the
present knowledge, in the vast majority of cases the deletion of
both markers indicates a complete deletion of the AZFb region.
However, as mentioned before, for predictive purposes prior to
TESE it is now – and in contrast to the previous guidelines –
mandatory to perform additional analyses with the following
second choice markers: sY105 (present) and sY121 or sY1224
(absent) for the proximal border and sY143 or sY1192 (absent)
and sY153 (present) for the distal border (Fig. 3B). The markers
sY114 and sY152 are not recommended anymore because these
are mapping to more than one genomic region. A more accurate
definition of the breakpoints can be defined by consulting the
above-mentioned ‘MSY breakpoint mapper’.
AZFc (b2/b4)
The two markers sY254 and sY255 are specific for the DAZ
gene, which is present in the reference Y chromosome sequence
in four copies arranged in two complexes of two genes each in
head-to-head orientation located in the palindromes P2 and P1,
respectively, in the reference MSY sequence (Saxena et al.,
2000). The absence of both markers indicates deletion of the
entire AZFc region, which removes all copies of DAZ. According
to current knowledge, the deletion of only one of these two
markers is impossible and should be always regarded as a meth-
odological error.
The vast experience accumulated until now has shown that
when both markers sY254 and sY255 are deleted, a diagnosis of
complete deletion of the AZFc region can be made. Some studies
have shown that the AZFc deletion pattern is rather constant,
although not always identical (Kuroda-Kawaguchi et al., 2001;
Luetjens et al., 2002). The primers indicated by Kuroda-Kawagu-
chi et al. (2001) and the analysis of sY160 (heterochromatin mar-
ker) permit the laboratory to determine if the deletion
corresponds to the b2/b4 pattern (Fig. 3B). Terminal deletions
(absence of sY160) are more often associated with mosaic karyo-
type (46,XY/45,X) and thus karyotype analysis should be
requested. The presence of 45,X cell lines has been considered a
negative prognostic factor for the presence of testicular sperma-
tozoa (Jaruzelska et al., 2001).
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AZFbc (P5/distal P1 or P4/distal P1)
The complete deletion of both AZFb and AZFc regions is indi-
cated by the lack of amplification of all four markers sY127,
sY134, sY254 and sY255. The use of more specific markers as
indicated by Repping et al. (2002) determine whether the dele-
tion corresponds to the P5/distal P1 or P4/distal P1 pattern
(sY116 is positive in case of P4/distal P1 and absent in case of
P5/distal P1). This definition has clinical prognostic value as
stated above (Kleiman et al. 2011). Also, in these patients it is
worthwhile to test for sY160 (heterochromatine marker) to
define whether it is a terminal deletion.
Interpretation of the results, control and repetition of the test
The protocol suggested by these guidelines (see appendix) has
been conceived and optimized so that each of the two multiplex
reactions contains a marker for each AZF region. Thus, when a
complete deletion occurs in a sample both PCR reactions should
show the lack of amplification for the marker specific for that
region. While partial deletions of the AZFa and AZFb region, as
indicated by the lack of amplification of only one marker for the
relevant region, are possible, the elective deletion of only sY254
or sY255 should always be regarded as a methodological error. If
only one marker for AZFa or AZFb is deleted, the deletion must
first be carefully confirmed (see below) and then the entire
region should be studied in more detail. This event, however, is
presently regarded as exceptional. In case of AZFabc deletion (all
the eight Yq markers are absent), the interpretation of the
control markers is of outstanding importance (SRY and ZFX/Y)
to rule out technical problems.
PCR conditions should be carefully optimized in each labora-
tory according to the equipment available (e.g. type of Thermo-
cycler) and DNA quality. If the result is ambiguous and/or a
technical failure is suspected, the multiplex reaction should be
repeated. If the multiplex does not work for a specific DNA sam-
ple, the primer set may be run in simplex reactions. If the results
of both multiplex PCR consistently speak in favour of a deletion,
the deletion is confirmed. If the results of the two multiplexes are
not in agreement, the whole set of primers should be repeated in
simplex PCR, as there is no reason to repeat the test in the same
manner. It is known that simplex PCR is less subject to amplifica-
tion failure and it is strongly advised to repeat the amplification
at a lower annealing temperature. There is no general advice as
to the number of repetitions. The test should be repeated until
the results are clear and reproducible (good laboratory practice).
REPORTING
Reports should be written in a standardized format and should
be clear to the non-specialist. Guidelines on how to write reports
on the outcome of molecular genetics investigations on a patient
can be found at the EMQN web site. In general, reports must be
clear, concise, accurate, fully interpretative, credible and author-
itative. Hand-written reports are not acceptable. Reports must
include the following information:
• clear identification of the laboratory
• date of referral and reporting
• patient identification: full name, date of birth and unique lab-
oratory accession/identification number
• restatement in some form of the clinical question being asked
(e.g. diagnosis of microdeletion of the Y chromosome), and
the indication (e.g. azoospermia, ICSI, etc.)
• tissue studied (e.g. blood, buccal smear, etc.)
• method used (e.g. multiplex PCR amplification)
• outcome of the analysis: a tabular form of the various STS loci
analysed is preferred. Avoid the use of + and , which can be
misinterpreted. Use words instead (e.g. present/absent, or
similar)
• a written interpretation understandable by the non-specialist
• signatures of two independent assessors.
Examples of reports concerning the most frequent deletions
are provided in the supplementary materials.
ALTERNATIVE METHODS FOR Y MICRODELETION
TESTING
Since the publications of the first guidelines in 1999, several
alternative methods have been published to assess Y-chromo-
somal deletions. In addition, there are commercial kits on the
market, which, however, almost all contain an unnecessary high
number of markers (see Appendix B). This may lead to detection
of ‘false’ deletions, especially if the DNA quality and PCR condi-
tions are suboptimal (Aknin-Seifer et al., 2003, 2005). Moreover,
the large majority of kits do not allow the validation of suspected
deletions by single PCR (see supplementary material). Recently,
Vogt & Bender (2013) proposed a multiplex PCR based on gene-
specific markers. Although this approach allows the detection of
isolated gene-specific deletions, the extreme rarity and unclear
clinical significance of these deletions (Tyler-Smith & Krausz,
2009) preclude its use in the routine diagnostics.
(A)
(B)
Figure 4 Twelve-year experience with the EAA/EMQN external quality con-
trol scheme. The number of participating labs has steadily increased (A).
Genotyping error rates have steeply declined, while interpretation scores
gradually increased (B).
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Alternative methods partially based on the guidelines proto-
cols have been developed using capillary electrophoresis, real-
time PCR, MLPA and array-CGH (Osborne et al., 2007; Kozina
et al., 2011; Guo et al., 2012; Jiang et al., 2012; Segat et al., 2012)
Using the EAA/EMQN multiplexes, but adding a fluorescent
label to the primers, allows detection with capillary electropho-
resis. Some laboratories have adapted the proposed protocol
accordingly, and validated this in house (LH, personal commu-
nication). Real-time PCR has the advantage of being relatively
fast, because the protocol does not involve running an agarose
gel, but the equipment needed is not available in every labora-
tory. There is one publication comparing MLPA-based Y deletion
detection with other methods, but unfortunately only the
abstract is available in English (Jiang et al., 2012). Finally, micro-
array technology has also been proposed as an alternative assay,
but it does not seem to be very cost-effective and includes many
more markers than necessary (Osborne et al., 2007).
In conclusion, from the literature there is no evidence that the
addition of more than the advised STSs is advantageous for clini-
cal routine diagnostics. Any time a laboratory establishes a spe-
cific method, this needs to be validated on a large enough
number of samples including positive and negative controls to
estimate the specificity and sensitivity. For reporting, it is impor-
tant to specifically mention the method(s) used and not just
refer to them as ‘according to guidelines’, which only applies to
the two multiplexes with all markers described herein.
TWELVE-YEAR EXPERIENCE OF THE EAA/EMQN EQA
The laboratories performing AZF diagnostics should annually
join an EQA scheme. A respective scheme is available at the
EMQN that is carried out in collaboration with the EAA; online
registration to the scheme is available at www.emqn.org. During
each EAA/EMQN AZF scheme, three validated DNA samples
with mock clinical case descriptions are distributed to partici-
pating laboratories per year. It is fundamental that the DNA
samples received from the organizers of the EQA programme are
processed exactly in the same way as patients’ samples are
handled, including reporting. The results are assessed by at least
two independent reviewers. Both a general report summarizing
overall performance and common problems as well as individual
reports to each participant including specific recommendations
are issued. Laboratories receive a certificate in which their
performance is evaluated.
Between 2000 and 2012 the number of participating laborato-
ries almost tripled from 57 to 148 (Fig. 4A). The diagnostic error
rate (an incorrect genotype that would lead to a misdiagnosis)
decreased steeply during the first 5 years from almost 8% and
now fluctuates at around 1–2% (Fig. 4B). While more variable,
an assessment of the quality of diagnostic report content also
showed an increase and around 50% of analyses in the last
4 years have scored full marks which is a clear improvement on
the previous earlier time of the scheme. Recurrent interpretation
problems still arise owing to laboratories using an unnecessary
high number of markers, which are specifically included in com-
mercially available kits (see above). The two dips in interpreta-
tion scores in 2006 and 2012 (Fig. 4B) can be explained by an 46,
XX male included as an extraordinary case, which lead to recur-
ring problems in reporting positive markers, conclusions for
further testing (karyotyping needs to be recommended) and
prognostic value (no chance for TESE success).
Overall, the established EQA scheme is a successful tool to
improve the performance of participating laboratories and has
demonstrated an improvement on reporting practice and
decreasing diagnostic error rates.
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Data S1. Examples of reports concerning the most frequent deletions
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APPENDIX A
EXAMPLE OF A PCR PROTOCOL
Two multiplex reactions were designed for the analysis of the
three AZF deletion regions on the Y chromosome. Both multi-
plexes contain five fragments, that is, the three AZF loci and the
two control fragments SRY and ZFX/Y. Each laboratory should
set up and validate its own protocol. Here, we give an example of
the protocol validated and currently in use at the Institute of
Human Genetics in M€unster.
PCR kit: Quiagen Multiplex PCR Kit (Cat.No. 206143, Quiagen,
Hilden, Germany).
Preparation of 109 primer mix A and B (containing 2 lM each
primer). Primer mixes are prepared in batches sufficient for
about 100 reactions, and packaged in smaller size aliquots (suffi-
cient for 10 or 20 reactions) for storage at 20 °C.
The 50-lL PCR reaction mix contains:
25 lL 29 Quiagen Multiplex PCR MasterMix [containing Hot-
StarTaq DNA Polymerase, Qiagen Multiplex PCR Buffer (con-
taining 6 mM MgCl2) and dNTP Mix], 5 lL 109 Primer mix
(2 lM each primer), ~1 lg template DNA, sterile distilled water
to 50 lL.
Amplification conditions (as established using a Hybaid
Touch Down Thermocycler) start with an initial activation
step of 15 min at 95 °C, followed by 35 cycles of 30-sec dena-
turation (94 °C), 90-sec annealing (57 °C) and 60-sec elonga-
tion (72 °C), ended by a last elongation step of 10 min and
cooling to 4 °C.
Reaction products (30 lL) are separated on a 2% Agarose
(Peqbold Universal Agarose, Peqlab, Erlangen, Germany) plus
0.5% DNA Agar (Serva, Heidelberg, Germany) gels in 1 9 TBE
for 25V overnight. An example of both multiplexes is given in
Fig. A1.
1 2 3 4 5 6
1 2 3 4 5 6
Multiplex A 
ZFX/Y
SRY
495 bp
472 bp
Multiplex B 
ZFX/Y
SRY
495 bp
472 bp
sY254 380 bp (AZFc)
sY86 318 bp (AZFa)
sY127 274 bp (AZFb)
sY84 326 bp (AZFa)
sY134 301 bp (AZFb)
sY255 123 bp (AZFc)
Fig A1 Examples of both Multiplex PCRs. Multiplex A: lane 1 phi X-HeaIII
size marker, lane 2 water, lane 3 female DNA, lane 4 DNA of normal male,
lane 5 DNA of AZFb (P5/proximal P1)-deleted patient, lane 6 DNA of AZFc
(b2/b4)-deleted patient.
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APPENDIX B
LOCUS AND SEQUENCE OF THE PCR PRIMERS (FOR FURTHER INFO SEE ALSO ‘MSY BREAKPOINT MAPPER’)
Locus Primer Sequence Product
size [bp]
Genomic locus
UCSC ChrY.hg19a
Status in classic,
complete deletion
Format A and B
ZFX/Y ZFX/Y-F 5′-ACC RCT GTA CTG ACT GTG ATT ACA C-3′ 495 Present
ZFX/Y-R 5′-GCA CYT CTT TGG TAT CYG AGA AAG T-3′
SRY sY14-F 5′-GAA TAT TCC CGC TCT CCG GA-3′ 472 Present
sY14-R 5′-GCT GGT GCT CCA TTC TTG AG-3′
Format A
AZFa sY86-F 5′-GTG ACA CAC AGA CTA TGC TTC-3′ 318 Absent
sY86-R 5′ - ACA CAC AGA GGG ACA ACC CT - 3′
AZFb sY127-F 5′-GGC TCA CAA ACG AAA AGA AA-3′ 274 22570359–22570742 Absent
sY127-R 5′-CTG CAG GCA GTA ATA AGG GA-3′
AZFc sY254-F 5′-GGG TGT TAC CAG AAG GCA AA-3′ 380 25316193–25316572b Absent
sY254-R 5′-GAA CCG TAT CTA CCA AAG CAG C-3′
Format B
AZFa sY84-F 5′-AGA AGG GTC CTG AAA GCA GGT-3′ 326 Absent
sY84-R 5′-GCC TAC TAC CTG GAG GCT TC-3′
AZFb sY134-F 5′-GTC TGC CTC ACC ATA AAA CG-3′ 301 23555947–23556406 Absent
sY134-R 5′-ACC ACT GCC AAA ACT TTC AA-3′
AZFc sY255-F 5′-GTT ACA GGA TTC GGC GTG AT-3′ 123 26999443–26999566b Absent
sY255-R 5′-CTC GTC ATG TGC AGC CAC-3′
Extension analysis
AZFa
AZFa sY82-F 5′-ATC CTG CCC TTC TGA ATC TC-3′ 264 Present
sY82-R 5′-CAG TGT CCA CTG ATG GAT GA-3′
AZFa1 sY83-F 5′-CTT GAA TCA AAG AAG GCC CT-3′ 275–277 Absent
sY83-R 5′-CAA TTT GGT TTG GCT GAC AT-3′
AZFa1 sY1064-F 5′-GGG TCG GTG CAC CTA AAT AA-3′ 110 Absent
sY1064-R 5′-TGC ACT AAA GAG TGA TAA TAA ATT CTG-3′
AZFa2 sY1065-F 5′-TCA GGT ACT GTG ATG CCG TT-3′ 239 Absent
sY1065-R 5′-TGA AGA GGA CAC AAA GGG AAA-3′
AZFa2 sY1182-F 5′-ATG GCT TCA TCC CAA CTG AG-3′ 247 Absent
sY1182-R 5′-CAT TGG CCT CTC CTG AGA CT-3′
AZFa sY88-F 5′-TTG TAA TCC AAA TAC ATG GGC-3′ 123 Present
sY88-R 5′-CAC CCA GCC ATT TGT TTT AC-3′
AZFb
AZFb sY105-F 5′-AAG GGC TTC TTC TCT TGC TT-3′ 301 19357220–19357589 Present
sY105-R 5′-AGG GAG CTT AAA CTC ACC GT-3′
AZFb3 sY121-F 5′-AGT TCA CAG AAT GGA GCC TG-3′ 190 21052033–21052360 Absent
sY121-R 5′-CCT GTG ACT CCA GTT TGG TC-3′
AZFb3 sY1224-F 5′-GGC TTA AAC TTG GGA GGG TG-3′ 640 20611625–20612264 Absent
sY1224-R 5′-CAA AGA GCC TCC CAG ACC A-3′
AZFb4 sY143-F 5′-GCA GGA TGA GAA GCA GGT AG-3′ 311 23977880–23978312 Absent
sY143-R 5′-CCG TGT GCT GGA GAC TAA TC-3′
AZFb4 sY1192-F 5′-ACT ACC ATT TCT GGA AGC CG-3′ 255 24872541–24873141 Absent
sY1192-R 5′-CTC CCT TGG TTC ATG CCA TT-3′
AZFb sY153-F 5′-GCA TCC TCA TTT TAT GTC CA-3′ 139 24912639–25112794b Present
sY153-R 5′-CAA CCC AAA AGC ACT GAG TA-3′
gr/gr sY1291-F 5′-TAA AAG GCA GAA CTG CCA GG-3′ 527 Absent
sY1291-R 5′-GGG AGA AAA GTT CTG CAA CG-3′
gr/gr sY1191-F 5′-CCA GAC GTT CTA CCC TTT CG-3′ 385 Present
sY1191-R 5′-GAG CCG AGA TCC AGT TAC CA-3′
Hetero-chromatin sY160-F 5′-TAC GGG TCT CGA ATG GAA TA-3′ 236 58911807–58912042b
sY160-R 5′-TCA TTG CAT TCC TTT CCA TT-3′
1,2,3,4 markers with same numbers are interchangeable.
a
There are some differences in the genomic position of STSs between UCSC (hg19) and MSY breakpoint mapper, which is currently
still based on hg18.
b
Multicopy STSs. Only the most proximal/distal position needed to describe deletions are given.
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APPENDIX C
COMMERCIALLY AVAILABLE KITS AND THEIR CHARACTERISTICS WITH RESPECT TO THE EAA/EMQN GUIDELINES.
Name of the kit (producer) Fully respects the Guidelines (STSs) Confirmation step by simplex or duplex PCR
AB Analitica Noa No
Devyser Noa No
Diachem/Bird Yes Yes
Euroclone Strip test Yes No
Euroclone Yes No
Experteam Yes No
Promega 2.0 Noa No
Qiagen Nob No
aExcessive number of markers.
bDifferent STS panel, only one marker for AZFa.
cKits which are based on the standard gel electrophoresis method are shaded.
APPENDIX D
Useful web sites:
European Academy of Andrology (EAA):
http://www.andrologyacademy.net/
European Molecular Genetics Quality Network (EMQN):
http://www.emqn.org/
MSY breakpointmapper: http://breakpointmapper.wi.mit.edu/
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F. T€uttelmann: frank.tuettelmann@ukmuenster.de
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